A solution for “frozen” generic drug labels and closure of an orphan exclusivity loophole were among the bills sent by the House of Representatives to the Senate during the lame duck congressional session.
The US Food and Drug Administration would be allowed to revoke or refuse to grant orphan drug exclusivity for a product if the sponsor could not show that sales wouldn’t cover the full cost of development under the Fairness in Orphan Drug Exclusivity Act, HR 4712
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?